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Ankyrin polypeptides are cellular adapter proteins that tether integralmembrane proteins to
the cytoskeleton in a host of human organs. Initially identiﬁed as integral components of the
cytoskeleton in erythrocytes, a recent explosion in ankyrin research has demonstrated that
these proteins play prominent roles in cytoskeletal signaling pathways and membrane pro-
tein trafﬁcking/regulation in a variety of excitable and non-excitable cells including heart and
brain. Importantly, ankyrin research has translated from bench to bedside with the discov-
ery of human gene variants associatedwith ventricular arrhythmias that alter ankyrin–based
pathways. Ankyrin polypeptides have also been found to play an instrumental role in various
forms of sinus node disease and atrial ﬁbrillation (AF). Mouse models of ankyrin-deﬁciency
have played fundamental roles in the translation of ankyrin-based research to new clinical
understanding of human sinus node disease, AF, and ventricular tachycardia.
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INTRODUCTION
Ankyrin polypeptides are a family of adapter proteins that
link integral membrane proteins with the submembranous
actin/spectrin-based cytoskeleton. Ankyrin-R was identiﬁed in
the late 1970s as a critical link between several anion exchanger
isoforms and β-spectrin in red blood cells (Bennett, 1979). Over
30 years later, ankyrins are now widely regarded as key players in
the formation of protein complexes including ion channels and
transporters, cell adhesion molecules (CAMs), signaling proteins,
and cytoskeletal elements. In heart, ankyrin-associated protein
complexes organize specialized membrane-domains with distinct
electrical and structural properties in cardiac sinus node, atrial,
and ventricular cardiomyocytes.With particular emphasis given to
ankyrin-B and ankyrin-G, this review provides important insight
into the role of ankyrins in cardiac physiology as well as pro-
viding information on the link between ankyrin dysfunction and
human arrhythmias based primarily on data garnered frommouse
models.
ANKYRIN STRUCTURE AND FUNCTION
ANK1, ANK2, and ANK3 genes encode three classes of ankyrin
polypeptides (ankyrin-R, ankyrin-B, and ankyrin-G, respectively).
While ankyrin-R expression is primarily limited to erythrocytes,
neurons, and skeletal muscle, both ankyrin-B and ankyrin-G are
widely expressed (Bennett and Chen, 2001; Cunha and Mohler,
2006). Although each gene is alternatively spliced to produce pro-
tein products of variable size, canonical ankyrin gene products
include 210 kDankyrin-R,220 kDankyrin-B,and190 kDankyrin-
G (Figure 1; Bennett and Chen, 2001; Cunha and Mohler, 2006).
Ankyrin genes are large, and complex splicing events determine
cell-speciﬁc binding partners and function. For example, ANK1
contains over 40 exons resulting in gene products ranging from
−30 to +200kD (Bennett and Chen, 2001). The ANK2 gene spans
over 560 kb with>50 exons and diverse splice forms ranging from
−50 to 440 kD inbrain,heart, skeletalmuscle and thymus (Bennett
and Chen, 2001). ANK3 encodes numerous ankyrin-G isoforms
broadly expressed in epithelial tissue, kidney, skeletal and cardiac
muscle, and brain (Bennett and Chen, 2001). While the speciﬁc
role of alternatively spliced ankyrin isoforms is unknown, it is
likely that variability in expression contributes to organization and
maintenance of distinct subcellular domains in eukaryotic cells.
Canonical ankyrins are comprised of four functional domains:
the membrane-binding domain (MBD), the spectrin-binding
domain (SBD), the death domain (DD), and the C-terminal
domain (CTD; Figure 1; Hashemi et al., 2009). The MBD medi-
ates the majority of ankyrin interactions with integral membrane
proteins including voltage-gated Na+ and K+ channels, the Na/Ca
(NCX) exchanger, the Na+/K+ ATPase (NKA), the ammonium
transporter, the KATP channel, the inositol 1,4,5 trisphosphate
receptor (IP3R), and the anion exchanger (Table 1; Bennett and
Healy, 2009; Kline et al., 2009). Furthermore, the MBD interacts
with CAMs including CD44, E-cadherin, and L1-CAMs. Ankyrin
membrane-domains are multivalent for integral membrane pro-
tein binding, and therefore have the ability to coordinate large
membrane-associated protein complexes. For example, in car-
diomyocytes, a single ankyrin-B polypeptide can form a ternary
membrane protein complex including the NCX, NKA, and IP3R
(Mohler et al., 2005). While there is a homology in the MBD
across members of the ankyrin family, each ankyrin possesses a
unique set of binding partners (e.g., ankyrin-G and voltage-gated
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FIGURE 1 | Canonical ankyrin (R, B, G) domain organization.
Table 1 | Select ankyrin (R, B, G) interacting proteins and site of
protein binding.
Interacting protein Ankyrin Ankyrin domain (if known)
ION CHANNELS/TRANSPORTERS
Na/Ca exchanger B MBD
Voltage-gated Nav channel G MBD
Na/K ATPase B,G MBD
Anion exchanger (1, 2, 3) R MBD
Kir6.2 B MBD
IP3 receptor B MBD
Kv7 G MBD
Ammonium transporter R, G
ADHESION MOLECULES
Cadherin (N, E) G
L1-CAMs R, B, G MBD
CD44 R MBD
CYTOSKELETON
Beta-spectrin R, B, G SBD
Obscurin R, B, G CTD
MEMBRANETRAFFICKING
Clathrin R MBD
EHD3 B MBD
Tubulin R, B MBD
Dynactin-4 B SBD
MISCELLANEOUS
PP2A B SBD
Hdj1 B CTD
Fas G CTD
MBD,membrane-binding domain; SBD, spectrin-binding domain; CTD, C-terminal
domain.
Na+ and K+ channels, ankyrin-B and NCX, NKA, IP3R). The
ankyrin SBD links ankyrin to the actin-based cytoskeleton via
β-spectrin isoforms (Mohler et al., 2004c) thereby conferring
structural stability to larger protein networks. Apart from struc-
tural capacities, the SBD has also been demonstrated to bind other
proteins including the regulatory subunit (B56alpha) of the PP2A
family (Bhasin et al., 2007). Lastly, the DD andCTD together com-
prise the ankyrin “regulatory domain.” This domain regulates the
binding of ankyrin isoforms to large muscle proteins including
obscurin (Kontrogianni-Konstantopoulos et al., 2003; Cunha and
Mohler, 2008). However, beyond intermolecular interactions, this
domain associates with the ankyrin-BMBD (Abdi et al., 2006).
Relevant for this review, the ankyrin-B “regulatory domain” is the
site of themajority of human gene variants linkedwith arrhythmia
phenotypes.
ANKYRIN-B AND VENTRICULAR TACHYCARDIA
Defects in ankyrin have been linked to a variety of human diseases,
and play an integral role in cardiovascular disease and arrhythmia.
In heart, a growing number of inherited arrhythmia syndromes
have been linked to ankyrin dysfunction with mounting data that
ankyrin defects may also play a role in common forms of acquired
heart disease. The ﬁrst such disorder linked to ankyrin dysfunc-
tion was inherited long-QT syndrome (LQTS), characterized by
abnormalities on the electrocardiogram (ECG), and increased
susceptibility to polymorphic ventricular arrhythmias and sud-
den death. Mutations within ion channels that are involved in
the generation and termination of action potentials make up the
majority of inherited LQTS (Splawski et al., 2000). However, work
nearly a decade ago identiﬁed the ﬁrst loss-of-function gene vari-
ant in ANK2 in large pedigrees with LQTS (Mohler et al., 2003).
Since this initial discovery, ANK2 loss-of-function variants are
now well documented to cause dominantly inherited type 4 LQTS
(LQT4) and have been identiﬁed throughout the world in cohorts
with phenotypes linked with LQT4 (Mohler et al., 2004b, 2007).
Beyond loss-of-function mutations, analysis of large human pop-
ulations has linked ANK2 single-nucleotide polymorphisms with
alterations in the cardiacQT interval (Sedlacek et al., 2008) further
supporting the role of ankyrin-B in cardiac electrical regulation.
The development amousemodel heterozygous for a nullmuta-
tion in ankyrin-B (ankyrin-B+/−) was critical for understanding
the pathophysiology of the human disease. In fact, ankyrin-B+/−
mice phenocopy human LQT4. It is also imperative to high-
light that mice homozygous for null mutations in ankyrin-B
(ankyrin-B−/−) also demonstrate abnormalities on ECG that mir-
rors those of LQT4 with abnormal QT rate adaptation resulting
in greater QT prolongation with heart rate deceleration (Chauhan
et al., 2000 #2). In regards to the heterozygous model, ankyrin-
B+/−mice and humanANK2 E1425G carriers display bradycardia,
prolonged QT interval, heart rate variability, and episodes of
isorhythmic atrio-ventricular dissociation (Mohler et al., 2003;
Le Scouarnec et al., 2008). Furthermore, similar to their human
counterparts, ankyrin-B+/− mice display polymorphic ventricu-
lar tachycardia, syncope, and sudden cardiac death in response to
exercise and increased circulating catecholamines. In light of the
complex phenotype presented by human ANK2 variant carriers
Frontiers in Physiology | Cardiac Electrophysiology May 2012 | Volume 3 | Article 122 | 2
Smith et al. Ankyrins and arrhythmia
that includes ventricular and supraventricular defects, the disease
name was revised to the moniker “Ankyrin-B Syndrome.”
Great strides have been made over the past 10 years to establish
the link between ankyrin-deﬁciency and increased susceptibility
to cardiac arrhythmia. At the level of the single myocyte, loss of
ankyrin-B results in aberrant membrane targeting and regulation
of theNKA,NCX,KATP,and IP3R. Loss of these proteinsultimately
produces defects in intracellular Na+ and Ca2+ regulation, that in
the cardiomyocyte leads to increased sarcoplasmic reticulum cal-
cium load, inappropriate calcium release, and early and delayed
after depolarizations in the presence of high levels of circulating
catecholamines. Subsequent computational modeling has further
supported the link between ankyrin-deﬁciency, loss of membrane
function of NCX andNKA, intracellularNa+ andCa2+ accumula-
tion, and increased susceptibility of myocytes to develop SR Ca2+
overload (Wolf et al., 2010). Inparticular, the ankyrin-deﬁcient cel-
lular phenotype was illustrated to produce frequent spontaneous
Ca2+ release events and increased the incidence of pro-arrhythmic
after depolarizations during rapid pacing and/or elevated cate-
cholamines (Wolf et al., 2010). This biophysical phenotype was
independently conﬁrmed in a recent report investigating Ca2+
handling in intact cardiomyocytes isolated from ankyrin-B+/−
mice (Camors et al., 2012).
ANKYRIN-B AND SINUS NODE DISEASE
Beyond ventricular arrhythmias, loss-of-function variants in
ankyrin-B have more recently been linked with sinus node dys-
function (Le Scouarnec et al., 2008). Similar to the discovery
of the link between ANK2 and human ventricular phenotypes,
large human pedigrees were initially utilized to provide genetic
linkage between sinus node disease and the ANK2 locus. Related
directly to sinus node disease, two large European cohorts mutant
ANK2 alleles were shown to display highly penetrant bradycardia
and exaggerated heart rate variability. Immunoblotting of mus-
cle biopsies in affected individuals conﬁrmed loss of ankyrin-B
expression associated with the phenotype (Le Scouarnec et al.,
2008). The degree of penetrance and the age of onset of sinus
node dysfunction were truly remarkable in affected individuals.
Sinus node dysfunction is largely a disease of the elderly popu-
lation (Bernstein and Parsonnet, 1992). However, carriers of the
ANK2 mutation received pacemakers (devices implanted under-
neath the skin of the clavicle with leads attached to the heart
designed to pace the heart at a safe heart rate if the native con-
duction system falters) at a mean age of 30-extraordinarily rare in
clinical practice. Akin to these patients with ankyrin-B-associated
sinus node disease, mice lacking ankyrin-B display severe sinus
node dysfunction, with reduced expression of NKA, NCX, and
IP3R (Le Scouarnec et al., 2008). However, unlike ventricular
cardiomyocytes, ICa,L was also signiﬁcantly reduced in isolated
ankyrin-B+/− sinoatrial node cells, further altering calcium han-
dling and sinoatrial node automaticity (Le Scouarnec et al., 2008).
Together these data link ankyrin-B dysfunction to sinus node dis-
ease and provide key mechanistic insights into molecular basis for
the disease at the cellular level. Subsequent studies have provided
new insight into the role of ankyrin-B in cardiac pacing at the
level of the whole heart. This past year, regulation of automatic-
ity in wild-type and ankyrin-B+/− mouse hearts was examined
using optical mapping (Glukhov et al., 2010). As expected in wild-
type mice, isoproterenol accelerated the sinoatrial rate and shifted
the leading pacemaker site whereas acetylcholine had the oppo-
site effect. In contrast, following isoproterenol, ankyrin-B+/− mice
exhibited signiﬁcant beat-to-beat variability (bradycardia followed
by abrupt bursts of tachycardia), a disorganized shift of the leading
pacemaker, and multiple competing pacemaker foci- phenotypes
consistent with the human sinus node disease. Ankyrin-B+/−
mouse hearts also displayed reduced sensitivity to acetylcholine.
Collectively these data highlight the importance of the functional
anatomy of the entire sinoatrial node pacemaker complex, and
clearly demonstrate the role of ankyrin-B in cardiac automaticity
in humans and in mice.
ANKYRIN-B AND ATRIAL FIBRILLATION
This past year, the role of ankyrin-B in cardiovascular electro-
physiology and disease has continued to expand by the linkage of
ankyrin-B dysfunction in human atrial ﬁbrillation (AF; Cunha
et al., 2011). Speciﬁcally, individuals harboring ANK2 loss-of-
function alleles presented with a high incidence of early-onset
AF, commonly progressing to permanent AF. In line with this
ﬁnding, continuous telemetry ECG recordings from ankyrin-B-
deﬁcientmice revealed atrial arrhythmias similar to those observed
in human carriers of ANK2 variants, including bradycardia with
erratic atrial activity, lack of discrete P waves, and variable ven-
tricular response (Cunha et al., 2011). Ankyrin-B+/− mice also
showed increased susceptibility to induction of AFin response to
atrial burst pacing. Primary atrial myocytes from ankyrin-B+/−
mice displayed shortened action potentials, a hallmark of AF, and
a sharp decrease of l-type Ca2+ current. Subsequent molecular
studies determined that loss of l-type calcium current was due
to loss of Cav1.3, but not Cav1.2 in atrial cardiomyocytes also
explaining previously discovered reductions in ICa,L in sinoatrial
node myocytes (Le Scouarnec et al., 2008). Moreover, Cav1.3 was
identiﬁed as a novel ankyrin-B-interacting protein, and this direct
interaction was shown to be mediated by a short motif in the
C-terminus. As a ﬁnal link between ankyrin-B and AF, analysis
of human paroxysmal AF showed decreased ankyrin-B, as well as
Cav1.3 expression. Together, these data provided a new molecu-
lar mechanism underlying congenital AF, a new binding partner
for ankyrin-B in heart, and implicate ankyrin-B in the pathogen-
esis of common acquired forms of AF. These studies also provide
insight into how defects in a single protein can result in a broad
spectrum clinical disease with unique regional manifestations. In
other words, the complexity of “ankyrin-B syndrome” arises from
the fact that ankyrin-B is both broadly expressed in the heart and
forms distinct, region-speciﬁc macromolecular complexes.
ANKYRIN-B, ISCHEMIA, AND ARRHYTHMIAS
In addition to roles in congenital arrhythmias, ankyrin-B has
more recently been linked with more common forms of heart
disease. Electrical and structural remodeling in the peri-infarct
zone creates a substrate favorable for the initiation and mainte-
nance of reentrant arrhythmias following myocardial infarction,
in particular, ventricular ﬁbrillation and tachycardia. An essential
component of this remodeling process involves the redistribution
of ion channels and transporters in surviving myocytes near the
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infarct (Baba et al., 2005). Recently, ankyrin-B mRNA and pro-
tein levels, along with downstream ankyrin-B-associated channels
were identiﬁed as differentially regulated following coronary artery
occlusion in the canine (Hund et al., 2009). Speciﬁcally, a marked
increase in ankyrin-B mRNA levels 5 days post-occlusion were
seen, presumably in response to the observed decrease in protein
levels of ankyrin-B at the same time. Protein levels and/or mem-
brane expression of NCX, NKA, and IP3R were also decreased at
5 days post-occlusion, in line with their known role as ankyrin-
B-binding partners (Hund et al., 2009). These changes were
observed in absence of any changes to β2-spectrin. By 14 days post-
occlusion, ankyrin-B protein levels had returned to baseline, and
the recovery of NCX,NKA, and IP3R expression were, also, under-
way, consistent with the normalization of electrical remodeling
observed in thismodel.While these studies focus on a chronic stage
of myocardial infarction, ankyrin-B likely is involved in heart’s
response to acute ischemia. Speciﬁcally, ankyrin-B plays a pivotal
role in ATP-sensitive K+ channel (KATP) regulation. Ankyrin-B
associates with the KATP channel via the major subunit, Kir6.2,
a key component of the cellular apparatus required for intrinsic
cardioprotection from ischemia (Li et al., 2010). Hearts and iso-
lated cardiomyocytes lacking ankyrin-B display a loss of Kir6.2
membrane expression resulting in decreased membrane IK,ATP
(Li et al., 2010). KATP channels serve a cardioprotective role in
ischemia via a KATP channel-mediated shortening of the action
potential (Suzuki et al., 2001), hence decreased expression of KATP
could increase the susceptibility to arrhythmias. More recently,
we have observed similar changes in ankyrin and related proteins
(e.g., EHD family of trafﬁcking proteins) in a variety of animal
models of ischemic and non-ischemic disease and in human heart
failure (Gudmundsson et al., 2010, 2012). In summary, these data
suggest potential new roles for ankyrin-B in the processes of elec-
trical and structural remodeling in common forms of heart disease
(myocardial infarction/heart failure).
Clearly, loss of membrane ion channels and transporters is an
important link between ankyrin dysfunction and disease. How-
ever, recent ﬁndings suggest that ankyrin-B regulation extends
beyond these integral membrane proteins to cardiac signaling in
health and disease. For example, in ventricular myocytes, ankyrin-
B has also been identiﬁed as a binding partner of B56α, the
regulatory subunit of PP2A (Bhasin et al., 2007). PP2A is a
multifunctional serine/threonine phosphatase known to regulate
cardiac β-adrenergic signaling (Klein et al., 2003; De Arcangelis
et al., 2008). Cardiomyocytes lacking ankyrin-B expression dis-
play a marked loss of B56α (Bhasin et al., 2007). As inhibition
of B56α in myocytes results in RyR2 hyper-phosphorylation [by
calcium/calmodulin-dependent kinase II (CaMKII)] andmyocyte
electrical instability, it is reasonable to speculate that defects
in CaMKII-based signaling pathways may contribute to human
ankyrin-B-linked arrhythmias (Terentyev et al., 2009). In sum-
mary, work from the past decade has illustrated complex roles
for ankyrin-B in myocyte function and in disease. The multi-
factorial nature of ankyrin-B and its broad distribution present
unique challenges and opportunities as we consider the devel-
opment of therapies to treat patients with inherited or acquired
ankyrin-deﬁciency and associated disease.
ANKYRIN-G AND BRUGADA SYNDROME
While much focus has been placed on the role of ankyrin-B in
heart due in part to the identiﬁed cohorts of human patients with
ankyrin-B mutations, the inﬂuence of ankyrin polypeptides on
heart function extends beyond ankyrin-B. Speciﬁcally, ankyrin-
G has been shown to play roles in heart health and disease.
Importantly, similar to its role in neurons, ankyrin-G has been
shown to target Nav1.5, for maintenance of normal cardiac cell
excitability. Ankyrin-G and Na channels directly associate and
are co-localized in heart at the intercalated disk, where neigh-
boring cells are electrically and mechanically coupled. Silencing
of ankyrin-G in myocytes results in loss of Nav1.5 expression,
membrane targeting, and membrane current (Lowe et al., 2008).
Defects in ankyrin-G-based targeting pathway have been linked
to excitable cell disease. Interestingly, ankyrin-G has emerged as a
candidate inmultiple GWAS studies as associatedwith bipolar dis-
order (Ferreira et al., 2008 #2309; Scott et al., 2009 #5597). In heart,
disruption of ankyrin-G/Nav1.5 interaction has been linked to the
Brugada Syndrome, an autosomal-dominant, cardiac arrhythmia
syndrome characterized by ST segment elevation in the precordial
leads associated with right bundle branch block and T-wave inver-
sion (Antzelevitch et al., 2005). SCN5A encodes Nav1.5, and gene
variants account for nearly a third of Brugada Syndrome cases.
SCN5A variants largely lead to biophysical defects that disrupt the
inward sodium current, which is a key current in cellular depo-
larization during the action potential. A SCN5A variant (E1053K)
that is localized to the ankyrin-G-bindingmotif inNav1.5 and dis-
rupts ankyrin-G/Nav1.5 association results in Brugada Syndrome
(Mohler et al., 2004a). Mechanistically, this variant disrupts nor-
mal membrane targeting of Nav1.5 resulting in loss of membrane
sodium channel current density and impaired excitability (Mohler
et al., 2004a).
Beyond Nav1.5 membrane targeting, ankyrin-G plays addi-
tional roles in Nav1.5 membrane regulation via recruitment of
Nav1.5 regulatory proteins. Speciﬁcally,Hund et al. (2010) recently
demonstrated that βIV-spectrin is co-localized and interacts with
ankyrin-G and Nav1.5 at the cardiac intercalated disk. More-
over, βIV-spectrin through direct binding, targets CaMKII to the
intercalated disk to directly phosphorylate Nav1.5 at a speciﬁc
residue (571) in the DI–DII linker. This study revealed that the
βIV-spectrin/CaMKII complex has a direct effect on membrane
excitability, and mutant βIV-spectrin mice lacking CaMKII bind-
ing activity (qv3J) displayed defects in Nav1.5 phosphorylation,
activity, excitability, and heart function (Hund et al., 2010). Based
on these initial ﬁndings, it is interesting to consider the poten-
tial role of βIV-spectrin/ankyrin-G-based signaling platform in
regulating excitable cell function in human disease (Hund et al.,
2010).
Apart from regulating membrane excitability, ankyrin-G was
recently proposed to play secondary roles in regulation of interca-
lated disk structural integrity. Delmar and colleagues identiﬁed
ankyrin-G as member of a larger complex of Nav1.5 and gap
junctions at the cardiac desmosome (Sato et al., 2011). Loss of
ankyrin-G caused signiﬁcant changes in the subcellular distribu-
tion and abundance of desmosomal proteins. This complex could
potentially play key roles in arrhythmia susceptibility as human
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mutations in desmosomal genes have been linked with the devel-
opment of arrhythmogenic right ventricular dysplasia (Pilichou
et al., 2006), characterized by inﬂammation, ﬁbrosis or adiposis,
and susceptibility to cardiac arrhythmia and sudden cardiac death
(Sen-Chowdhry et al., 2010). In summary, based on the ability to
regulate both critical electrical and structural signaling, ankyrin-
G-based pathways have been shown to play key roles in myocyte
physiology and likely are a central key node for human structural
and electrical heart disease.
SUMMARY
The past decade has illustrated critical roles for ankyrins in
cardiac physiology and in disease. Unlike their classic roles in
the erythrocyte, ankyrins play dynamic roles in protein target-
ing and stability, and secondary unexpected roles in protein
regulation and cardiac signaling. While ankyrins are linked with
congenital ventricular and atrial arrhythmias, current data sug-
gest that these proteins serve central nodal points of regulation
for common forms of acute and chronic cardiovascular dis-
ease. Moreover, based on expression, it is not unreasonable that
ankyrins likely play key roles in other types of human cardiovas-
cular disease including inﬂammation and metabolic and vascular
disease.
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